Pucotenlimab, identified by its CAS number 2403647-03-8, is a monoclonal antibody designed for therapeutic applications, particularly in the field of immunology. It is engineered to target specific proteins involved in immune responses, which can be pivotal in treating various autoimmune diseases and conditions. As a biologic, Pucotenlimab is characterized by its complex structure, consisting of amino acid chains that form a specific three-dimensional configuration essential for its function. The substance is typically produced using recombinant DNA technology in mammalian cell systems, ensuring proper folding and post-translational modifications. Its mechanism of action generally involves binding to target antigens, modulating immune responses, and potentially inhibiting inflammatory pathways. Pucotenlimab's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are influenced by its protein nature, often requiring careful dosing and monitoring in clinical settings. As with many biologics, safety and efficacy profiles are established through rigorous clinical trials, and it may have specific storage and handling requirements due to its sensitivity to temperature and light.

Pucotenlimab

2403647-03-8: Pucotenlimab, identified by its CAS number 2403647-03-8, is a monoclonal antibody designed for therapeutic applications, particularly in the field of immunology. It is engineered to target specific proteins involved in immune responses, which can be pivotal in treating various autoimmune diseases and conditions. As a biologic, Pucotenlimab is characterized by its complex structure, consisting of amino acid chains that form a specific three-dimensional configuration essential for its function. The substance is typically produced using recombinant DNA technology in mammalian cell systems, ensuring proper folding and post-translational modifications. Its mechanism of action generally involves binding to target antigens, modulating immune responses, and potentially inhibiting inflammatory pathways. Pucotenlimab's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are influenced by its protein nature, often requiring careful dosing and monitoring in clinical settings. As with many biologics, safety and efficacy profiles are established through rigorous clinical trials, and it may have specific storage and handling requirements due to its sensitivity to temperature and light.

<p>Pucotenlimab (HX008) is an anti-PD-1 mAb that blocks PD-1/PD-L1/2 interactions, restoring immune function against solid tumours.</p>

CAS 2403647-03-8

Pucotenlimab

Pucotenlimab

Ref: TM-T77178